WO2006020684A3 - Methods of regulating differentiation and treating of multiple myeloma - Google Patents

Methods of regulating differentiation and treating of multiple myeloma Download PDF

Info

Publication number
WO2006020684A3
WO2006020684A3 PCT/US2005/028362 US2005028362W WO2006020684A3 WO 2006020684 A3 WO2006020684 A3 WO 2006020684A3 US 2005028362 W US2005028362 W US 2005028362W WO 2006020684 A3 WO2006020684 A3 WO 2006020684A3
Authority
WO
WIPO (PCT)
Prior art keywords
differentiation
multiple myeloma
methods
treating
pleiotrophin
Prior art date
Application number
PCT/US2005/028362
Other languages
French (fr)
Other versions
WO2006020684A2 (en
Inventor
James Berenson
Chen Haiming
Melinda S Gordon
Original Assignee
Inst Multiple Myeloma And Bone
James Berenson
Chen Haiming
Melinda S Gordon
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Multiple Myeloma And Bone, James Berenson, Chen Haiming, Melinda S Gordon filed Critical Inst Multiple Myeloma And Bone
Priority to CA002579764A priority Critical patent/CA2579764A1/en
Priority to AU2005272920A priority patent/AU2005272920B2/en
Priority to EP05783932A priority patent/EP1789552A2/en
Publication of WO2006020684A2 publication Critical patent/WO2006020684A2/en
Publication of WO2006020684A3 publication Critical patent/WO2006020684A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0645—Macrophages, e.g. Kuepfer cells in the liver; Monocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/44—Vessels; Vascular smooth muscle cells; Endothelial cells; Endothelial progenitor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/069—Vascular Endothelial cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/5055—Cells of the immune system involving macrophages
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57426—Specifically defined cancers leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/165—Vascular endothelial growth factor [VEGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/11—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/50—Proteins
    • C12N2533/54—Collagen; Gelatin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Abstract

The present invention provides methods of regulating cellular differentiation, including differentiation of stem cells and trans-differentiation of monocytes/macrophages using agonists or antagonists of pleiotrophin or a pleiotrophin receptor, as well as related methods of treating cancers associated with pleiotrophin-regulated differentiation and angiogenesis, including, e.g., multiple myeloma.
PCT/US2005/028362 2004-08-10 2005-08-10 Methods of regulating differentiation and treating of multiple myeloma WO2006020684A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CA002579764A CA2579764A1 (en) 2004-08-10 2005-08-10 Methods of regulating differentiation and treating of multiple myeloma
AU2005272920A AU2005272920B2 (en) 2004-08-10 2005-08-10 Methods of regulating differentiation and treating of multiple myeloma
EP05783932A EP1789552A2 (en) 2004-08-10 2005-08-10 Methods of regulating differentiation and treating of multiple myeloma

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60013204P 2004-08-10 2004-08-10
US60/600,132 2004-08-10

Publications (2)

Publication Number Publication Date
WO2006020684A2 WO2006020684A2 (en) 2006-02-23
WO2006020684A3 true WO2006020684A3 (en) 2006-09-14

Family

ID=35908115

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/028362 WO2006020684A2 (en) 2004-08-10 2005-08-10 Methods of regulating differentiation and treating of multiple myeloma

Country Status (4)

Country Link
EP (1) EP1789552A2 (en)
AU (1) AU2005272920B2 (en)
CA (1) CA2579764A1 (en)
WO (1) WO2006020684A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2547248T3 (en) 2006-04-28 2015-10-02 Delenex Therapeutics Ag Antibodies that bind to the extracellular domain of the ALK receptor tyrosine kinase
AU2012244351B2 (en) * 2006-04-28 2014-05-15 Delenex Therapeutics Ag Antibodies binding to the extracellular domain of the Receptor Tyrosine Kinase ALK
AU2010365277B2 (en) 2010-12-06 2017-01-05 Thd S.P.A. Method for the diagnosis of a carcinoma and uses thereof
GB201204816D0 (en) * 2012-03-19 2012-05-02 Brainco Biopharma S L Transgenic animal model of mood disorders
WO2015191668A1 (en) * 2014-06-10 2015-12-17 Institute For Myeloma & Bone Cancer Research Anti-cancer effects of proteasome inhibitors in combination with glucocorticoids, arsenic containing compounds, and ascorbic acid

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0937461A1 (en) * 1996-07-10 1999-08-25 Meiji Milk Products Company Limited Use of mk family as hematopoietic factor
WO2000020869A1 (en) * 1998-10-06 2000-04-13 Georgetown University Detection of pleiotrophin
WO2001027629A1 (en) * 1999-10-12 2001-04-19 Centre National De La Recherche Scientifique (Cnrs) Diagnosis of pathologies of mononucleated blood cells
WO2001064944A1 (en) * 2000-02-29 2001-09-07 Barnes-Jewish Hospital MODULATION OF PLEIOTROPHIN SIGNALING BY RECEPTOR-TYPE PROTEIN TYROSINE PHOSPHATASE β/$g(z)

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4769330A (en) 1981-12-24 1988-09-06 Health Research, Incorporated Modified vaccinia virus and methods for making and using the same
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
GB8508845D0 (en) 1985-04-04 1985-05-09 Hoffmann La Roche Vaccinia dna
US4777127A (en) 1985-09-30 1988-10-11 Labsystems Oy Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
GB8702816D0 (en) 1987-02-07 1987-03-11 Al Sumidaie A M K Obtaining retrovirus-containing fraction
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
WO1989001973A2 (en) 1987-09-02 1989-03-09 Applied Biotechnology, Inc. Recombinant pox virus for immunization against tumor-associated antigens
AP129A (en) 1988-06-03 1991-04-17 Smithkline Biologicals S A Expression of retrovirus gag protein eukaryotic cells
CA1340323C (en) 1988-09-20 1999-01-19 Arnold E. Hampel Rna catalyst for cleaving specific rna sequences
CA2066053C (en) 1989-08-18 2001-12-11 Harry E. Gruber Recombinant retroviruses delivering vector constructs to target cells
CA2039718C (en) 1989-08-31 2003-02-25 John J. Rossi Chimeric dna-rna catalytic sequences
US6365730B1 (en) 1990-06-19 2002-04-02 Gene Shears Pty. Limited DNA-Armed ribozymes and minizymes
AU8200191A (en) 1990-07-09 1992-02-04 United States of America, as represented by the Secretary, U.S. Department of Commerce, The High efficiency packaging of mutant adeno-associated virus using amber suppressions
DE69123979T2 (en) 1990-10-12 1997-04-30 Max Planck Gesellschaft MODIFIED RIBOZYMS
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
DE4216134A1 (en) 1991-06-20 1992-12-24 Europ Lab Molekularbiolog SYNTHETIC CATALYTIC OLIGONUCLEOTIDE STRUCTURES
JP3534749B2 (en) 1991-08-20 2004-06-07 アメリカ合衆国 Adenovirus-mediated gene transfer into the gastrointestinal tract
US5652094A (en) 1992-01-31 1997-07-29 University Of Montreal Nucleozymes
US5631359A (en) 1994-10-11 1997-05-20 Ribozyme Pharmaceuticals, Inc. Hairpin ribozymes

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0937461A1 (en) * 1996-07-10 1999-08-25 Meiji Milk Products Company Limited Use of mk family as hematopoietic factor
WO2000020869A1 (en) * 1998-10-06 2000-04-13 Georgetown University Detection of pleiotrophin
WO2001027629A1 (en) * 1999-10-12 2001-04-19 Centre National De La Recherche Scientifique (Cnrs) Diagnosis of pathologies of mononucleated blood cells
WO2001064944A1 (en) * 2000-02-29 2001-09-07 Barnes-Jewish Hospital MODULATION OF PLEIOTROPHIN SIGNALING BY RECEPTOR-TYPE PROTEIN TYROSINE PHOSPHATASE β/$g(z)

Non-Patent Citations (22)

* Cited by examiner, † Cited by third party
Title
BLOOD, vol. 106, no. 11, Part 1, November 2005 (2005-11-01), 47th Annual Meeting of the American Society of Hematology; Atlanta, GA, USA; 10-13 December 2005, pages 117A - 118A, ISSN: 0006-4971 *
BLOOD, vol. 106, no. 11, Part 1, November 2005 (2005-11-01), 47th Annual Meeting of the American Society of Hematology; Atlanta, GA, USA; 10-13 December 2005, pages 37A, ISSN: 0006-4971 *
BLOOD, vol. 106, no. 11, Part 1, November 2005 (2005-11-01), 47th Annual Meeting of the American Society of Hematology; Atlanta, GA, USA; 10-13 December 2005, pages 701A, ISSN: 0006-4971 *
BLOOD, vol. 106, no. 11, Part 1, November 2005 (2005-11-01), 47th Annual Meeting of the American Society of Hematology; Atlanta, GA, USA; 10-13 December 2005, pages 704A, ISSN: 0006-4971 *
BLOOD, vol. 106, no. 11, Part 1, November 2005 (2005-11-01), 47th Annual Meeting of the American Society of Hematology; Atlanta, GA, USA; 10-13 December 2005, pages 948A, ISSN: 0006-4971 *
BLOOD, vol. 106, no. 11, Part 1, November 2005 (2005-11-01), 47th Annual Meeting of the American Society of Hematology; Atlanta, GA, USA; 10-13 December 2005, pages 954A, ISSN: 0006-4971 *
CHOUDHURI R ET AL: "An angiogenic role for the neurokines midkine and pleiotrophin in tumorigenesis.", CANCER RESEARCH, vol. 57, no. 9, 1 May 1997 (1997-05-01), pages 1814 - 1819, XP002122390, ISSN: 0008-5472 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; November 2005 (2005-11-01), CAMPBELL R A ET AL: "Blocking pleiotrophin activity inhibits multiple myeloma (MM) cell growth in vitro and in a severe combined immunodeficient (SCID)-hu murine model of human MM.", XP002386899, Database accession no. PREV200600182484 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; November 2005 (2005-11-01), CHEN H ET AL: "Circulating Tie2-expressing cells are increased in multiple myeloma patients, correlate with serum pleiotrophin levels and may develop from this myeloma angiogenic and growth factor.", XP002386901, Database accession no. PREV200600184863 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; November 2005 (2005-11-01), CHEN H ET AL: "Transdifferentiation of monocytes into endothelial cells by pleiotrophin.", XP002386898, Database accession no. PREV200600182761 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; November 2005 (2005-11-01), GORDON M S ET AL: "Identification of novel receptors on myeloma cells and monocytes that contribute to myeloma tumor proliferation and angiogenesis.", XP002386902, Database accession no. PREV200600184876 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; November 2005 (2005-11-01), HUERTA-YEPEZ S ET AL: "Overexpression and preferential nuclear translocation of the transcription factor Yin Yang 1 (YY1) in human bone marrow-derived multiple myeloma", XP002386903, Database accession no. PREV200600185762 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; November 2005 (2005-11-01), YEH H S ET AL: "Serum pleiotrophin is a new multiple myeloma tumor marker that also predicts clinical status.", XP002386900, Database accession no. PREV200600185785 *
JÄGER R ET AL: "Serum levels of the angiogenic factor pleiotrophin in relation to disease stage in lung cancer patients.", BRITISH JOURNAL OF CANCER, vol. 86, no. 6, 18 March 2002 (2002-03-18), pages 858 - 863, XP002386065, ISSN: 0007-0920 *
MURAMATSU T: "Midkine and pleiotrophin: two related proteins involved in development, survival, inflammation and tumorigenesis.", JOURNAL OF BIOCHEMISTRY, vol. 132, no. 3, September 2002 (2002-09-01), pages 359 - 371, XP009009323, ISSN: 0021-924X *
PUFE T ET AL: "Expression of pleiotrophin, an embryonic growth and differentiation factor, in rheumatoid arthritis.", ARTHRITIS & RHEUMATISM, vol. 48, no. 3, March 2003 (2003-03-01), pages 660 - 667, XP002386067, ISSN: 0004-3591 *
SHARIFI B G ET AL: "Data Supplement", pages 1 - 27, XP002386069, Retrieved from the Internet <URL:http://atvb.ahajournals.org/cgi/data/ 01.ATV.0000222017.05085.8e/DC1/1> *
SHARIFI B G ET AL: "Pleiotrophin induces transdifferentiation of monocytes into functional endothelial cells.", ARTERIOSCLER. THROMB. VASC. BIOL., vol. 26, no. 6, June 2006 (2006-06-01), pages 1273 - 1280, XP008065340, ISSN: 1524-4636 *
SHARIFI B G ET AL: "Pleiotrophin regulates transdifferentiation of monocytic cells into endothelial-like cells", CIRCULATION, vol. 110, no. 17, Suppl. III, 26 October 2004 (2004-10-26), 77th Scientific Meeting of the American Heart Association; New Orleans, LA, USA; 7-10 November 2004, pages 72, XP008060778, ISSN: 0009-7322 *
VACHEROT F ET AL: "Involvement of heparin affin regulatory peptide in human prostate cancer.", THE PROSTATE, vol. 38, no. 2, 1 February 1999 (1999-02-01), pages 126 - 136, XP002386064, ISSN: 0270-4137 *
YEH H S ET AL: "Serum pleiotrophin levels are elevated in multiple myeloma patients and correlate with disease status.", BRITISH JOURNAL OF HAEMATOLOGY, vol. 133, no. 5, June 2006 (2006-06-01), pages 526 - 529, XP002386070, ISSN: 0007-1048 *
YEH H-J ET AL: "Upregulation of pleiotrophin gene expression in developing microvasculature, macrophages, and astrocytes after acute ischemic brain injury.", THE JOURNAL OF NEUROSCIENCE, vol. 18, no. 10, 15 May 1998 (1998-05-15), pages 3699 - 3707, XP002386066, ISSN: 0270-6474 *

Also Published As

Publication number Publication date
AU2005272920B2 (en) 2011-05-12
EP1789552A2 (en) 2007-05-30
CA2579764A1 (en) 2006-02-23
AU2005272920A1 (en) 2006-02-23
WO2006020684A2 (en) 2006-02-23

Similar Documents

Publication Publication Date Title
WO2006026570A3 (en) Use of stem cells to generate inner ear cells
WO2006083782A3 (en) Directed differentiation of embryonic stem cells and uses thereof
WO2007062188A3 (en) Activin-actriia antagonists and uses for promoting bone growth
WO2007047468A3 (en) Immunomodulation using placental stem cells
WO2004029219A3 (en) Cell-based rna interference and related methods and compositions
TW200631594A (en) Toll like receptor 3 antagonists, methods and uses
WO2005072706A3 (en) Nanosuspensions of anti-retroviral agents for increased central nervous system delivery
ZA200606056B (en) Selected CGRP antagonists, methods for the production thereof and their use as medicaments
WO2007014930A3 (en) Polyammonium/polysiloxane copolymers
WO2008127226A3 (en) P13 kinase antagonists
IN2009DN05670A (en)
ZA200800431B (en) Selected cgrp antagonists, methods for the production thereof and their use as medicaments
WO2006097320A3 (en) Macromolecular nucleotide links and methods for their use
WO2007133290A8 (en) Anti-ox40l antibodies and methods using same
MX2007008723A (en) Yersinia spp. polypeptides and methods of use.
MX337423B (en) Humanized anti-beta7 antagonists and uses therefor.
WO2007014373A3 (en) Novel cells, compositions, and methods
UA101346C2 (en) Normal;heading 1;heading 2;heading 3;4-PHENYLPYRANE-3,5-DIONES, 4-PHENYLTHIOPYRANE-3,5-DIONES AND 2-PHENYLCYCLOHEXANE-1,3,5-TRIONES AS HERBICIDES
WO2007073497A3 (en) Calcium channel antagonists
WO2007073554A3 (en) Block copolymer particles
WO2008066630A3 (en) Methods for reprogramming adult somatic cells and uses thereof
WO2005087793A3 (en) Immunostimulatory compositions and uses thereof
WO2006020684A3 (en) Methods of regulating differentiation and treating of multiple myeloma
WO2006105234A3 (en) Hybrid inorganic nanoparticles, methods of using and methods of making
WO2005103229A3 (en) Transgenomic mitochondria, transmitochondrial cells and organisms, and methods of making and using

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2005272920

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2579764

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2005783932

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2005272920

Country of ref document: AU

Date of ref document: 20050810

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005272920

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2005783932

Country of ref document: EP